159 related articles for article (PubMed ID: 31755660)
21. Fas ligand expression in the bone marrow in myelodysplastic syndromes correlates with FAB subtype and anemia, and predicts survival.
Gupta P; Niehans GA; LeRoy SC; Gupta K; Morrison VA; Schultz C; Knapp DJ; Kratzke RA
Leukemia; 1999 Jan; 13(1):44-53. PubMed ID: 10049059
[TBL] [Abstract][Full Text] [Related]
22. Hypocellularity in myelodysplastic syndrome is an independent factor which predicts a favorable outcome.
Yue G; Hao S; Fadare O; Baker S; Pozdnyakova O; Galili N; Woda BA; Raza A; Wang SA
Leuk Res; 2008 Apr; 32(4):553-8. PubMed ID: 17888511
[TBL] [Abstract][Full Text] [Related]
23. Double 20q- anomaly in myelodysplastic syndrome.
Ohyashiki K; Murakami T; Ohyashiki JH; Kodama A; Sakai N; Ito H; Toyama K
Cancer Genet Cytogenet; 1992 Feb; 58(2):174-6. PubMed ID: 1551084
[TBL] [Abstract][Full Text] [Related]
24. Angiogenesis in relation to clinical stage, apoptosis and prognostic score in myelodysplastic syndromes.
Lundberg LG; Hellström-Lindberg E; Kanter-Lewensohn L; Lerner R; Palmblad J
Leuk Res; 2006 Mar; 30(3):247-53. PubMed ID: 16099505
[TBL] [Abstract][Full Text] [Related]
25. Myelodysplastic syndrome of del 20q with plasma cell dysplasia.
Saito N; Higashiura K; Ehata K; Kurosawa S; Honma K; Abe M; Kimura A; Suzuki M; Nakamura S; Shiku H; Kean Ooi H
J Clin Exp Hematop; 2011; 51(2):141-5. PubMed ID: 22104314
[TBL] [Abstract][Full Text] [Related]
26. Aberration of p73 promoter methylation in de novo myelodysplastic syndrome.
Zhao Y; Gu S; Guo J; Zhang Z; Zhang X; Li X; Chang C
Hematology; 2012 Sep; 17(5):275-82. PubMed ID: 22971533
[TBL] [Abstract][Full Text] [Related]
27. Morphology, cytogenetics, and survival in myelodysplasia with del(20q) or ider(20q): a multicenter study.
Mullier F; Daliphard S; Garand R; Dekeyser M; Cornet Y; Luquet I; Talmant P; Richebourg S; Jamar M; Dogné JM; Chatelain C; Michaux L; Chatelain B
Ann Hematol; 2012 Feb; 91(2):203-13. PubMed ID: 21744002
[TBL] [Abstract][Full Text] [Related]
28. De novo myelodysplastic syndrome (MDS) with deletion of the long arm of chromosome 20: a subtype of MDS with distinct hematological and prognostic features?
Wattel E; Laï JL; Hebbar M; Preudhomme C; Grahek D; Morel P; Bauters F; Fenaux P
Leuk Res; 1993 Nov; 17(11):921-6. PubMed ID: 8231232
[TBL] [Abstract][Full Text] [Related]
29. Hypoxia-inducible factor-1α expression indicates poor prognosis in myelodysplastic syndromes.
Tong H; Hu C; Zhuang Z; Wang L; Jin J
Leuk Lymphoma; 2012 Dec; 53(12):2412-8. PubMed ID: 22632108
[TBL] [Abstract][Full Text] [Related]
30. Imbalance between apoptosis and telomerase activity in myelodysplastic syndromes: possible role in ineffective hemopoiesis.
Ohshima K; Karube K; Shimazaki K; Kamma H; Suzumiya J; Hamasaki M; Kikuchi M
Leuk Lymphoma; 2003 Aug; 44(8):1339-46. PubMed ID: 12952227
[TBL] [Abstract][Full Text] [Related]
31. Myelodysplastic syndrome macrophages have aberrant iron storage and heme oxygenase-1 expression.
Nybakken G; Gratzinger D
Leuk Lymphoma; 2016 Aug; 57(8):1893-902. PubMed ID: 26758041
[TBL] [Abstract][Full Text] [Related]
32. Prognostic evaluation of ALIP and CD34 immunostaining in IPSS-R subgroups of myelodysplastic syndromes.
Xiong B; Nie Y; Tang Z; Xue M; Zuo X
Pathology; 2017 Aug; 49(5):526-533. PubMed ID: 28669578
[TBL] [Abstract][Full Text] [Related]
33. Quantity of clonal cells detected by conventional cytogenetic analysis correlates with bone marrow blasts and survival in myelodysplastic syndromes.
Kim M; Chung S; See CJ; Yoon SS; Kim BK; Kim HK; Lee DS
Leuk Res; 2012 Feb; 36(2):163-8. PubMed ID: 21920602
[TBL] [Abstract][Full Text] [Related]
34. EVI1 expression predicts outcome in higher-risk myelodysplastic syndrome patients.
Liu L; Wang J; Jiang Y; Xie H; Tang X; Li Q; Wang H; Zou P; Miao Z; Lv Y; Wang H; Cao Z; Zhao Z
Leuk Lymphoma; 2018 Dec; 59(12):2929-2940. PubMed ID: 29846125
[TBL] [Abstract][Full Text] [Related]
35. Myelodysplastic syndrome with isolated deletion of chromosome 20q: an indolent disease with minimal morphological dysplasia and frequent thrombocytopenic presentation.
Gupta R; Soupir CP; Johari V; Hasserjian RP
Br J Haematol; 2007 Oct; 139(2):265-8. PubMed ID: 17764468
[TBL] [Abstract][Full Text] [Related]
36. In patients with myelodysplastic syndromes with del(5q), factors other than age and sex contribute to the prognostic advantage, which diminishes over time.
Lauseker M; Schemenau J; Strupp C; Kündgen A; Gattermann N; Hasford J; Germing U
Br J Haematol; 2015 Sep; 170(5):687-93. PubMed ID: 25960152
[TBL] [Abstract][Full Text] [Related]
37. High PRAME expression is associated with poor survival and early disease progression in myelodysplastic syndromes with a low bone marrow blast percentage.
Shiseki M; Ishii M; Ohwashi M; Wang YH; Tanaka N; Osanai S; Yoshinaga K; Mori N; Tanaka J
Leuk Lymphoma; 2021 Oct; 62(10):2448-2456. PubMed ID: 34013846
[TBL] [Abstract][Full Text] [Related]
38. Comparison of blast percentage calculated based on bone marrow all nucleated cells and non-erythroid cells in myelodysplastic syndromes with erythroid hyperplasia.
Mashima K; Ikeda T; Kawaguchi SI; Toda Y; Ito S; Ochi SI; Nagayama T; Umino K; Minakata D; Nakano H; Yamasaki R; Morita K; Kawasaki Y; Sugimoto M; Ishihara Y; Ashizawa M; Yamamoto C; Fujiwara SI; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
Ann Hematol; 2019 May; 98(5):1127-1133. PubMed ID: 30474718
[TBL] [Abstract][Full Text] [Related]
39. The characteristics and prognostic analysis in 213 myeloid malignancy patients with del(20q): a report of a single-center case series.
Pan J; Wu C; Xue Y; Qiu H; Chen S; Zhang J; Bai S; Wu Y; Wang Y; Shen J; Gong Y
Cancer Genet; 2014 Mar; 207(3):51-6. PubMed ID: 24699042
[TBL] [Abstract][Full Text] [Related]
40. Bone marrow blasts level predicts prognosis in patients with refractory cytopenia with multilineage dysplasia.
Wang H; Wang XQ; Xu XP; Lin GW
Eur J Haematol; 2009 Dec; 83(6):550-8. PubMed ID: 19737310
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
